While these data support the potential utility of CSF VE‐Cadherin in early AD, it has not been compared to other imaging or fluid biomarkers of BBB dysfunction; thus, additional studies are warranted to understand how CSF VE‐Cadherin relates to established biomarkers of BBB dysfunction and to confirm its role in the progression of ADRD. Here, CDH5 is linked to Alzheimer disease.